Nr4A1 modulates inflammation-associated intestinal fibrosis and dampens fibrogenic signaling in myofibroblasts
Vivek Krishna Pulakazhi Venu, Laurie Alston, Mircea Iftinca, Yi-Cheng Tsai, Matthew Stephens, Vineetha Warriyar K. V., Sonia Rehal, Grace Hudson, Holly Szczepanski, Pierre‐Yves von der Weid, Christophe Altier, Simon A. Hirota
2021American Journal of Physiology-Gastrointestinal and Liver Physiology61 citationsDOIOpen Access PDF
Abstract
Fibrosis and increased muscle thickening contribute to stricture formation and intestinal obstruction, a complication that occurs in 30%-50% of patients with CD within 10 yr of disease onset. More than 50% of those who undergo surgery to remove the obstructed bowel will experience stricture recurrence. To date, there are no drug-based approaches approved to treat intestinal strictures. In the current submission, we identify NR4A1 as a novel target to treat inflammation-associated intestinal fibrosis.
Topics & Concepts
FibrosisMedicineMyofibroblastInflammationThickeningInflammatory bowel diseaseComplicationGastroenterologyDownregulation and upregulationDiseaseInternal medicinePathologyBiologyChemistryBiochemistryPolymer scienceGeneNuclear Receptors and SignalingMacrophage Migration Inhibitory Factor